Clinical evaluation of Ga-67 DFO-DAS-fibrinogen scintigraphy

Gallium-67 DFO-DAS-fibrinogen scintigraphy was performed in four patients for the detection of tumor and thrombosis. No adverse reactions were noted. Scintigrams in a patient with bronchogenic carcinoma accompanied with atelectasis showed abnormal uptake not only in the cancerous region but also in the whole atelectatic region as well. In a patient with hepatoma after TAE, a slight uptake of tracer was noted in the area surrounding the tumorous region, indicating accumulation of the tracer in the microthrombi. In two patients with venous thrombosis, no abnormal uptake was seen. The long interval from the onset of thrombus formation and the commencement of anticoagulant therapy prior to scintigraphy may have caused the false-negative scans in these cases. Further evaluation is necessary with regard to the usefulness of this technique in clinical practice.